Retractable Technologies Inc (RVP)
AMEXHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$0.71-0.43%
Close 2026-09-04 · 1-day change
AMEXHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
Retractable Technologies aims to reduce operating losses from -$7.7 million in 2025-Q4 to about -$6.2 million in 2026-Q1. Revenue peaked at $10.4 million in 2025-Q2, showing potential for growth. The company has a clear priority to improve income and stabilize sales.
Revenue declined from $10.4 million in 2025-Q2 to $7.2 million in 2026-Q1, showing weak sales momentum. Operating losses remain large and persistent near -$6.2 million. The company is still loss-making with no clear signs of sustained recovery.
The market expects about -2% revenue decline over the next year and implies a 3-year growth rate near -15%. Our fair value of $3.35 suggests the stock is cheap versus peers but reflects ongoing losses and weak growth.
Breaks if: Free cash flow yield remains below -35% or worsens
Breaks if: Operating income worsens beyond -$6.2 million in 2026-Q1
Continue efforts to reduce operating losses and improve operating income through cost savings and operational efficiencies.
Stated as a priority in 2 of last 2 quarters. Operating losses were $5.1 million in 2026-Q2 and $6.2 million in 2026-Q1. The April 2026 workforce reduction is expected to save $2.2 million annually. The trajectory shows persistent operating losses but management is delivering cost savings initiatives.
“Operating loss of $5.1 million for the period, reduction in force in April 2026 expected to result in cost savings.”
“In April 2026, the Company reduced its workforce by approximately 16%, expected to save $2.2 million annually.”
Breaks if: Revenue falls below $7.2 million in any quarter
Focus on increasing revenue and stabilizing sales volumes amid fluctuating customer purchasing patterns and product demand.
Stated as a priority in 2 of last 2 quarters. Revenue declined from $10.4 million in 2025-Q2 to $7.2 million in 2026-Q2 and from $8.3 million in 2025-Q1 to $7.2 million in 2026-Q1. Management cites fluctuating customer orders and product mix changes. The trajectory shows declining revenue with ongoing efforts to stabilize sales.
“Total net sales of $7.2 million for Q2 2026, down from $10.4 million in Q2 2025 due to timing of EasyPoint product orders.”
“Total net sales of $7.2 million for Q1 2026, down from $8.3 million in Q1 2025, affected by product mix and distributor transaction costs.”
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story in the healthcare sector. RVP is currently facing weak financial performance and high risk, but it operates in an environment that could provide tailwinds if larger companies in the sector perform well.
The market seems to have priced in a low expectation for RVP's recovery, as it is viewed as cheap compared to peers. However, there is a significant expectations gap, indicating that investors are not anticipating strong performance in the near term.
Fundamentals are likely to remain under pressure in the near term, with management focused on reducing losses and stabilizing revenue. Recent results show persistent operating losses and declining revenue, which management is trying to address through cost-saving initiatives.
The future performance of RVP hinges on broader sector trends, particularly the performance of key industry players like ISRG, BDX, and RMD. If these companies continue to perform well, it could lift RVP, but any negative shifts could further impact its already weak fundamentals.
Over the next 1 to 3 years, RVP's outlook remains uncertain, with a focus on management's ability to stabilize operations amidst a challenging environment. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.